Austedo Xr is owned by Teva.
Austedo Xr contains Deutetrabenazine.
Austedo Xr has a total of 8 drug patents out of which 0 drug patents have expired.
Austedo Xr was authorised for market use on 17 February, 2023.
Austedo Xr is available in tablet, extended release;oral dosage forms.
Austedo Xr can be used as treatment of tardive dyskinesia, treatment of tardive dyskinesia; a method of treating huntington's chorea, a method of treating huntington's chorea.
The generics of Austedo Xr are possible to be released after 10 June, 2041.
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8524733 | TEVA | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Apr, 2031
(7 years from now) | |
US9550780 | TEVA | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
Sep, 2033
(10 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11564917 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
US10959996 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
US11446291 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
US11357772 | TEVA | Methods for the treatment of abnormal involuntary movement disorders |
Mar, 2036
(12 years from now) | |
US11179386 | TEVA | Analogs of deutetrabenazine, their preparation and use |
Mar, 2038
(14 years from now) | |
US11311488 | TEVA | Osmotic dosage forms comprising deutetrabenazine and methods of use thereof |
Jun, 2041
(18 years from now) |
Drugs and Companies using DEUTETRABENAZINE ingredient
Market Authorisation Date: 17 February, 2023
Treatment: Treatment of tardive dyskinesia; A method of treating huntington's chorea
Dosage: TABLET, EXTENDED RELEASE;ORAL
48
United States
11
Japan
9
China
8
Australia
7
European Union
6
Hong Kong
6
Canada
5
Spain
3
Denmark
3
Brazil
3
Korea, Republic of
3
Israel
3
South Africa
2
Poland
2
Singapore
2
Argentina
2
EA
2
New Zealand
2
Croatia
2
Chile
2
Portugal
2
Mexico
2
Lithuania
2
Hungary
1
India
1
RS
1
Norway
1
Cyprus
1
Peru
1
Taiwan
1
Colombia
1
Slovenia
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic